NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...
Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...
Prof Nicholas Schwab and his colleagues found a biomarker which allows to tell in advance if therapy with glatirameracetate will be efficient in an individual MS patent. Treatment with interferon or ...
Hosted on MSN
Biomarker provides clear criteria for choice of treatment options in multiple sclerosis
Treatment with interferon or with glatiramer acetate? This question arises for many patients who receive a diagnosis of multiple sclerosis (MS) for the first time. Until now, the choice between the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results